HBM Healthcare Investments (Cayman) Ltd. - 09 Feb 2023 Form 3 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
10%+ Owner
Signature
/s/ Jean-Marc LeSieur, Managing Director
Issuer symbol
MLYS
Transactions as of
09 Feb 2023
Net transactions value
$0
Form type
3
Filing time
09 Feb 2023, 20:04:14 UTC
Previous filing
12 Nov 2021
Next filing
16 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MLYS Series A Preferred Stock 09 Feb 2023 Common Stock 1,941,368 Direct F1
holding MLYS Series B Preferred Stock 09 Feb 2023 Common Stock 964,238 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering ("IPO"), each share of Series A Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series A Preferred Stock have no expiration date.
F2 Upon the closing of the Issuer's IPO, each share of Series B Preferred Stock beneficially owned by the reporting person will automatically convert, for no additional consideration, into the number of shares of Common Stock reported in Column 3. These shares of Series B Preferred Stock have no expiration date.